Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
What this study shows
Ku-0063794 is a specific ATP-competitive mTOR inhibitor blocking mTORC1 and mTORC2.
At a glance
| Evidence type | M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: In vitro; cells) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is. |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | In vitro; cells |
| Journal | The Biochemical journal |
| Year | 2009 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1042/BJ20090489 · PMID 19402821 · Free full text (PMC2708931) |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Ku-0063794 (ATP-competitive mTOR inhibitor) |
| Target | mTORC1 & mTORC2 |
| Model | In vitro; cells |
| Effect | Ku-0063794 is a specific mTOR inhibitor blocking both complexes (Akt/S6K/SGK signaling) |
In the Atlas
Related topics
Links in the pathway map
- Supports ATP-competitive mTOR inhibitors inhibits mTORC1
- Supports ATP-competitive mTOR inhibitors inhibits mTORC2
More studies on this topic
- mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1) (2008)
- An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 (2009)
- Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 (2009)
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor (2010)
Was this page useful?
Thank you. Your answer was counted anonymously.